减低强度预处理与清髓性预处理在急性髓系白血病首次完全缓解患者异基因造血细胞移植前的长期疗效:开放标签随机3期试验的回顾性随访
该研究对原随机3期试验进行回顾性10年随访,比较减低强度预处理与清髓性预处理在急性髓系白血病首次完全缓解患者中的长期疗效。结果显示两组10年累积复发率相同(均为30%),无证据表明减低强度预处理增加晚期复发风险。
要点
- 两组10年累积复发率相同(30% vs 30%,Gray检验p=0.99)。
- 10年无病生存率减低强度组55% vs 清髓性组43%(HR 0.76,95%CI 0.51-1.14;p=0.19)。
- 10年非复发死亡率减低强度组16% vs 清髓性组26%(亚分布HR 0.60,95%CI 0.32-1.11;Gray检验p=0.10)。
核心结论
- 无证据表明减低强度预处理较清髓性预处理增加晚期复发风险。
- 鉴于原试验中减低强度预处理组早期并发症和毒性较低,对于60岁以下、首次完全缓解期移植的急性髓系白血病患者,采用中等程度降低全身照射剂量的减低强度预处理可能是首选预处理策略。
研究设计与样本
- 原随机3期试验纳入18-60岁、中危或高危急性髓系白血病、器官功能充足、有HLA匹配同胞供者或至少9/10 HLA等位基因匹配无关供者的患者。
- 患者按1:1随机分配至减低强度预处理组(氟达拉滨120 mg/m2联合4次2 Gy全身照射)或清髓性预处理组(6次2 Gy全身照射联合环磷酰胺120 mg/kg)。
- 本次为回顾性长期随访分析,数据来自各参与研究中心医疗报告及医生和患者访谈,随访完整性指数99%。
- 存活患者中位随访时间9.9年(IQR 8.5-11.4),在意向治疗人群中计算10年时事件率并用Gray检验比较。
- 原试验随机分配195例患者至减低强度预处理组(n=99)或清髓性预处理组(n=96)。
主要发现
- 全部研究人群中累积复发率两组相同:减低强度预处理组30%(95%CI 20-39)vs 清髓性预处理组30%(95%CI 21-40);Gray检验p=0.99。
- 复发中位时间:减低强度预处理组5.0个月(IQR 3.0-8.8)vs 清髓性预处理组9.5个月(IQR 4.5-20.5)。
- 10年无病生存率:减低强度预处理组55%(95%CI 45-66)vs 清髓性预处理组43%(95%CI 34-55);HR 0.76(95%CI 0.51-1.14);p=0.19。
- 10年非复发死亡率:减低强度预处理组16%(95%CI 8-24)vs 清髓性预处理组26%(95%CI 17-36);亚分布HR 0.60(95%CI 0.32-1.11);Gray检验p=0.10。
- 继发恶性肿瘤:减低强度预处理组94例中6例(6%)vs 清髓性预处理组90例中5例(6%);p=1.00。
临床怎么用
- 作者认为,对于60岁以下、首次完全缓解期移植的急性髓系白血病患者,采用中等程度降低全身照射剂量的减低强度预处理可能是首选的预处理策略。
局限性
- 原试验随访时间短,无法明确减低强度预处理是否较清髓性预处理增加晚期复发风险,故本研究进行回顾性10年随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of the intensity of conditioning before allogeneic haemopoietic cell transplantation (HCT) has been studied in a randomised phase 3 trial comparing reduced-intensity conditioning with myeloablative conditioning in patients with acute myeloid leukaemia in first complete remission. Because of the short follow-up of the original trial, whether reduced-intensity conditioning increases the risk of late relapse compared with myeloablative conditioning remained unclear. To address this question, we present retrospective 10-year follow-up data of this trial and focus on late relapse. METHODS: The original randomised phase 3 trial included patients aged 18-60 years, with intermediate-risk or high-risk acute myeloid leukaemia, an adequate organ function, and an available HLA-matched sibling donor or an unrelated donor with at least nine out of ten HLA alleles matched. Patients were randomly assigned (1:1) to 120 mg/m2 fludarabine combined with four 2 Gy doses of total-body irradiation (reduced-intensity conditioning) or six 2 Gy doses of total-body irradiation and 120 mg/kg cyclophosphamide (myeloablative conditioning). The primary and secondary efficacy endpoints of this trial have been published previously. In this retrospective, long-term follow-up analysis, data were collected from medical reports from individual participating study centres, and from physician and patient interviews. Endpoints included in this analysis were cumulative relapse incidence, overall survival, disease-free survival, and non-relapse mortality in the original study population and in patients alive and relapse-free at 12 months after HCT (landmark analysis). 10-year time to event rates were calculated in the intention-to-treat population and were compared with the Gray test. The trial is registered with ClinicalTrials.gov, number NCT00150878. FINDINGS: In the original trial, 195 patients were randomly assigned to receive reduced-intensity conditioning (n=99) or myeloablative conditioning (n=96). For this retrospective analysis, data were collected with a nearly complete follow-up (completeness index 99%). Median follow-up time for surviving patients was 9·9 years (IQR 8·5-11·4), during which the cumulative incidence of relapse in the complete study population was identical in both groups (30% [95% CI 20-39] in the reduced-intensity conditioning group vs 30% [21-40] in the myeloablative conditioning group; Gray test p=0·99). Relapse occurred at a median of 5·0 months (IQR 3·0-8·8) in the reduced-intensity conditioning group versus 9·5 months (4·5-20·5) in the myeloablative conditioning group. 10-year disease-free survival was 55% (95% CI 45-66) in the reduced-intensity conditioning group and 43% (34-55) in the myeloablative conditioning group (hazard ratio [HR] 0·76 [0·51-1·14]; p=0·19). 10-year non-relapse mortality was 16% (95% CI 8-24) in the reduced-intensity conditioning group and 26% (17-36) in the myeloablative conditioning group (subdistribution HR 0·60 [95% CI 0·32-1·11]; Gray test p=0·10). The incidence of long-term toxicities associated with total-body irradiation was comparable; secondary malignancies occurred in six (6%) of 94 patients in the reduced-intensity conditioning group and five (6%) of 90 in the myeloablative conditioning group (p=1·00). INTERPRETATION: There is no evidence that reduced-intensity conditioning increases the risk of late relapse compared with myeloablative conditioning. Given that the reduced-intensity conditioning group in the original trial was associated with lower early morbidity and toxicity, reduced-intensity conditioning with moderately reduced total-body irradiation doses could be the preferred conditioning strategy for patients with acute myeloid leukaemia who are younger than 60 years and transplanted in first complete remission. FUNDING: None.
引用
- Fasslrinner F, Schetelig J, Burchert A, et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018. PMID: 29550384. doi:10.1016/S2352-3026(18)30022-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。